Vanda Pharmaceuticals (VNDA) Non-Current Deferred Tax Liability (2014 - 2017)

Vanda Pharmaceuticals has reported Non-Current Deferred Tax Liability for 4 years, with the latest figure at -$386000.0 in Q4 2017.

• Quarterly Non-Current Deferred Tax Liability fell 157.96% year-over-year to -$386000.0 in Q4 2017, while the trailing twelve-month figure through Dec 2017 was -$386000.0 (down 157.96% YoY) and the FY2017 annual result came in at -$386000.0, down 157.96% from the prior year.
• Non-Current Deferred Tax Liability eased to -$386000.0 in Q4 2017 per VNDA's latest filing, from $666000.0 in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $1.1 million in Q4 2015 and troughed at -$386000.0 in Q4 2017.
• A 4-year average of $346500.0 and a median of $336000.0 in 2014 frame the typical range for Non-Current Deferred Tax Liability.
• The sharpest annual moves came in 2015 and 2017: Non-Current Deferred Tax Liability jumped 18233.33% in 2015, then slumped 157.96% in 2017.
• Over 4 years, Non-Current Deferred Tax Liability stood at $6000.0 in 2014, then surged by 18233.33% to $1.1 million in 2015, then plunged by 39.45% to $666000.0 in 2016, then tumbled by 157.96% to -$386000.0 in 2017.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered -$386000.0, $666000.0, and $1.1 million for Q4 2017, Q4 2016, and Q4 2015 respectively.